What Is Vilon?
Vilon is a synthetic dipeptide bioregulator with sequence Lys-Glu (KE), originally isolated from thymus tissue and subsequently synthesized as a sequence-defined compound. With a molecular weight of just ~275 Da (C₁₁H₂₁N₃O₅), it is one of the shortest bioactive peptides ever documented with significant in-vivo effects. Developed within Vladimir Khavinson's peptide bioregulator program, Vilon has been studied for more than 40 years for chromatin remodeling, immune-gene expression modulation, thymic function support, T-cell restoration, hematopoiesis, and potential lifespan extension in animal models. Modern RUO vendors supply it as a 20 mg lyophilized vial for laboratory research; historical Eastern European practice included ampoule injections and capsules in clinical settings. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Research Background
Vilon emerged from early work on Timalin (thymic extract) and short peptide bioregulators at the St. Petersburg Institute of Bioregulation and Gerontology. It was identified as a minimal active motif within thymic proteins — demonstrating that just two amino acids (Lys-Glu) could recapitulate significant immune and aging effects of larger thymic preparations. Over decades, Vilon has been investigated across chromatin biology (deheterochromatinization of aging lymphocytes), murine longevity (20–40% lifespan extension), immune restoration, and exploratory work in tumor biology, cardiovascular aging, and kidney disease. It remains one of the most research-backed members of the Khavinson dipeptide class, with multiple PubMed-indexed mechanistic studies.
Mechanism of Action
Vilon's primary documented mechanism is chromatin reactivation: it induces unrolling (deheterochromatinization) of facultative heterochromatin in aging lymphocytes, reactivates ribosomal genes by decondensing nucleolus organizer regions, and releases immune-related genes silenced by age-related heterochromatin condensation — increasing protein synthesis capacity in immune cells. Importantly, Vilon does not decondense pericentromeric structural heterochromatin, distinguishing it structurally from Epitalon and Livagen. At the receptor/signaling level, Vilon upregulates IL-2, normalizes CD4/CD8 ratios, and increases NK cell cytotoxicity. More recent work (Khavinson et al., 2023) documents regulation of SIRT1, PARP1, and PARP2 gene expression in mesenchymal stem cells — extending its epigenetic reach into longevity-pathway genes beyond the immune compartment.
Quick Reference
Research Indications
Chromatin Remodeling & Immune Gene Regulation
Deheterochromatinization in Aging Lymphocytes
Vilon's most robustly documented effect: Lezhava et al. (Mech. Ageing Dev., 2004) and Khavinson et al. (2006) demonstrated that Vilon induces unrolling of total heterochromatin in cultured lymphocytes from elderly subjects, reactivates ribosomal genes by decondensing nucleolus organizer regions, and releases genes silenced by facultative heterochromatin — restoring synthetic and immune-gene expression capacity lost with age. Notably, Vilon does not decondense pericentromeric structural heterochromatin, suggesting a distinct selectivity profile compared to Epitalon and Livagen.
Immune Gene-Expression Modulation
By reversing age-related epigenetic silencing in immune cells, Vilon reactivates immune-related genes and increases lymphocyte synthetic activity. This underpins its role as a chromatin-level immune-gene modulator, potentially counteracting the progressive T-cell dysfunction and immune senescence seen in aging.
Immune Restoration & Thymic Function
T-Cell Population Normalization
Vilon modulates immune function by restoring balance in T-lymphocyte populations (including CD4/CD8 ratios and NK cell activity), supporting T-cell differentiation, and improving immune responses in aging or immunocompromised states. It functions as an immune modulator — reducing dysregulation rather than broadly stimulating — with effects on thymic activity and CD5 T-cell subsets.
Immunocorrection in Suppressed Immunity
Within the Thymalin/Thymogen/Vilon ecosystem, Vilon is described as supporting immune correction in states of suppressed immunity — post-trauma, post-surgery, and after chemo-radiotherapy. It may help normalize immune cell populations, improve lymphocyte function, and support overall immune resilience and hematopoiesis recovery.
Longevity & Systemic Aging
Lifespan Extension in Animal Models
Khavinson & Anisimov (Mech. Ageing Dev.) reported that chronic Vilon administration in female CBA mice extended mean lifespan by 20–40%, with no adverse developmental effects, hormonal disruptions, or organ toxicities. These are among the most striking data in the Khavinson bioregulator literature, though they require independent human confirmation.
Tumor Biology — Mixed Findings
Some studies suggest Vilon has tumor-inhibitory properties (reduced mammary tumor incidence in HER-2/neu transgenic mice); other data show complex interactions with tumor biology. Findings are mixed and context-dependent; Vilon should be used with particular caution in cancer contexts until this question is better resolved.
Cardiovascular & Kidney Geroprotection
Vilon is included in some Khavinson multi-organ geroprotective protocols for cardiovascular aging and chronic kidney disease, with claimed benefits on immune balance and tissue repair. Evidence is observational and extrapolated from broader bioregulator data; not confirmed by independent RCTs.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
Peptide Interactions
Reported Research Time Points
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Quality Indicators
Verified Marker
Identity: L-Lys-L-Glu (KE) Confirmed by MS & Sequence Analysis
Product clearly identifies the compound as Vilon, L-Lys-L-Glu or KE dipeptide. Identity confirmed by mass spectrometry (MW ≈ 275.30 Da, formula C₁₁H₂₁N₃O₅) and sequence analysis. Mislabeling or confusion with other thymic peptides is a documented quality concern.
Verified Marker
Purity ≥99% HPLC with CoA
Reputable RUO vendors supply Vilon at ≥99% purity by HPLC. A CoA (Certificate of Analysis) from a third-party lab should accompany the vial, confirming purity, identity, and absence of related peptide impurities.
Verified Marker
White Lyophilized Powder — Clear Reconstitution
Correct Vilon appears as a white to off-white lyophilized powder forming a clear, colorless solution when reconstituted with bacteriostatic water. Discoloration, cloudiness, or unexpected particulates indicate a quality problem.
Quality Concern
Sequence Mislabeling or Conflation with Other Thymic Peptides
Some secondary listings or low-quality vendors conflate Vilon (Lys-Glu / KE) with Thymogen (Glu-Trp), Timalin, or other thymic extracts. The described verification process includes verifying the exact amino acid sequence on the CoA.
Quality Concern
Missing CoA, Unclear Origin, or Ambiguous Concentration
Lack of a verifiable CoA, unclear manufacturing origin, or ambiguous peptide concentration and excipient information makes product verification impossible and suggests substandard manufacturing.
Research Citations
- KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging
Khavinson VK, Linkova NS, Ashapkin VV — Adv Gerontol, 2023 - Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK — Int J Mol Sci, 2022 - Expression of argyrophilic proteins in nucleolar organizer regions of human thymocytes and thymic epitheliocytes under coculturing with vilon and epithalon peptides
Raikhlin NT, Bukaeva IA, Smirnova EA — Bull Exp Biol Med, 2004 - Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice
Anisimov VN, Khavinson VK, Provinciali M — Int J Cancer, 2002 - Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice
Alimova IN, Bashurin DA, Popovich IG — Vopr Onkol, 2002 - Chromatin remodeling and the effects of Vilon on structural and facultative heterochromatin in aging lymphocytes
Lezhava T et al. — Mech Ageing Dev, 2004 - Khavinson development attribution. Avolio et al. Int J Mol Sci. 2022;23(7):3607. Khavinson peptide attribution.
Vilon is a synthetic dipeptide bioregulator with sequence Lys-Glu (KE), originally isolated from thymus tissue and subsequently synthesized as a sequence-defined compound. With a molecular weight of just ~275 Da (C₁₁H₂₁N₃O₅), it is one of the shortest bioactive peptides ever documented with significant in-vivo effects. Developed within Vladimir Khavinson's peptide bioregulator program, Vilon has been studied for more than 40 years for chromatin remodeling, immune-gene expression modulation, thymic function support, T-cell restoration, hematopoiesis, and potential lifespan extension in animal models. Modern RUO vendors supply it as a 20 mg lyophilized vial for laboratory research; historical Eastern European practice included ampoule injections and capsules in clinical settings.